Floatz logo

Osilodrostat

Cushing Disease Due To Pituitary Adenoma

University of BasrahSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Cushing Disease Due To Pituitary Adenoma cohort.

Asset / SponsorPhaseRating
Cabergoline
University of Basrah
Phase 4BB
Pasireotide
RECORDATI GROUP
Phase 4B

Same molecule, other indications

Osilodrostat is also rated in:

adrenal gland hyperfunctionActive
BBB
Indicative · Phase 4
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →